|
Brainsway Ltd. (Bway) DCF Valoración
IL | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BrainsWay Ltd. (BWAY) Bundle
¡Mejore sus estrategias de inversión con la calculadora DCF de Brainsway Ltd. (Bway)! Explore las finanzas de cerebro auténticas, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estas modificaciones afectan el valor intrínseco de Brainsway Ltd. (Bway).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.1 | 22.1 | 29.7 | 27.2 | 31.8 | 34.8 | 38.2 | 41.9 | 45.9 | 50.3 |
| Revenue Growth, % | 0 | -4.52 | 34.46 | -8.36 | 16.96 | 9.63 | 9.63 | 9.63 | 9.63 | 9.63 |
| EBITDA | -6.6 | -3.5 | -4.7 | -11.5 | -2.3 | -7.6 | -8.4 | -9.2 | -10.0 | -11.0 |
| EBITDA, % | -28.5 | -15.7 | -15.76 | -42.15 | -7.27 | -21.87 | -21.87 | -21.87 | -21.87 | -21.87 |
| Depreciation | 2.8 | 1.6 | 1.7 | 1.5 | 1.3 | 2.4 | 2.7 | 2.9 | 3.2 | 3.5 |
| Depreciation, % | 12.1 | 7.34 | 5.68 | 5.64 | 4.21 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| EBIT | -9.4 | -5.1 | -6.4 | -13.0 | -3.6 | -10.1 | -11.0 | -12.1 | -13.3 | -14.5 |
| EBIT, % | -40.6 | -23.04 | -21.44 | -47.79 | -11.48 | -28.87 | -28.87 | -28.87 | -28.87 | -28.87 |
| Total Cash | 21.9 | 17.2 | 57.3 | 47.9 | 46.0 | 32.9 | 36.1 | 39.6 | 43.4 | 47.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5.5 | 5.6 | 6.3 | 4.8 | 3.8 | 7.0 | 7.7 | 8.4 | 9.2 | 10.1 |
| Account Receivables, % | 23.84 | 25.31 | 21.35 | 17.82 | 11.89 | 20.04 | 20.04 | 20.04 | 20.04 | 20.04 |
| Inventories | .3 | .4 | .2 | 3.8 | 3.7 | 2.1 | 2.3 | 2.5 | 2.7 | 3.0 |
| Inventories, % | 1.32 | 2 | 0.67438 | 14.12 | 11.69 | 5.96 | 5.96 | 5.96 | 5.96 | 5.96 |
| Accounts Payable | 1.3 | .8 | 1.1 | 1.1 | .8 | 1.4 | 1.5 | 1.6 | 1.8 | 2.0 |
| Accounts Payable, % | 5.71 | 3.54 | 3.72 | 4.11 | 2.38 | 3.89 | 3.89 | 3.89 | 3.89 | 3.89 |
| Capital Expenditure | -3.3 | -2.5 | -2.2 | 1.9 | -2.4 | -2.8 | -3.1 | -3.4 | -3.7 | -4.1 |
| Capital Expenditure, % | -14.33 | -11.2 | -7.55 | 7.12 | -7.51 | -8.12 | -8.12 | -8.12 | -8.12 | -8.12 |
| Tax Rate, % | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 |
| EBITAT | -9.8 | -5.3 | -6.4 | -13.3 | -3.9 | -10.1 | -11.0 | -12.1 | -13.3 | -14.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14.8 | -6.9 | -7.1 | -12.0 | -4.1 | -11.4 | -12.2 | -13.4 | -14.7 | -16.1 |
| WACC, % | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -56.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -16 | |||||||||
| Terminal Value | -388 | |||||||||
| Present Terminal Value | -287 | |||||||||
| Enterprise Value | -343 | |||||||||
| Net Debt | -10 | |||||||||
| Equity Value | -333 | |||||||||
| Diluted Shares Outstanding, MM | 17 | |||||||||
| Equity Value Per Share | -20.08 |
What You Will Get
- Authentic BrainsWay Data: Preloaded financials – covering everything from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the effects of changes on BrainsWay’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasts.
- Efficient and Precise: Eliminate the need to build models from the ground up while ensuring accuracy and adaptability.
Key Features
- Customizable Treatment Parameters: Adjust essential factors such as treatment duration, patient demographics, and expected outcomes.
- Instant Treatment Effectiveness Analysis: Quickly assesses the efficacy of various treatment protocols.
- Clinical-Grade Precision: Utilizes BrainsWay's real-world clinical data for accurate treatment evaluations.
- Effortless Outcome Comparisons: Evaluate different treatment scenarios and analyze results with ease.
- Efficiency Booster: Streamline the process without the need for complex treatment modeling from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review BrainsWay Ltd.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and apply the results to your investment decisions.
Why Choose BrainsWay Ltd. (BWAY)?
- Save Time: Quickly access advanced neurostimulation solutions without the lengthy setup.
- Enhance Treatment Outcomes: Proven technology and methodologies lead to improved patient results.
- Fully Customizable: Adapt our services to meet the specific needs of your practice.
- User-Friendly Interface: Intuitive design ensures ease of use for both practitioners and patients.
- Backed by Research: Supported by extensive clinical studies and recognized by healthcare professionals.
Who Should Use BrainsWay Ltd. (BWAY)?
- Healthcare Investors: Develop comprehensive valuation models for investment analysis in the medical sector.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within healthcare organizations.
- Consultants and Advisors: Deliver precise valuation insights for BrainsWay Ltd. (BWAY) to clients in the healthcare industry.
- Students and Educators: Utilize real-world data to enhance learning in financial modeling and healthcare economics.
- Medical Technology Enthusiasts: Gain insights into how companies like BrainsWay Ltd. (BWAY) are valued in the healthcare market.
What the Template Contains
- Pre-Filled Data: Includes BrainsWay Ltd.'s (BWAY) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze BrainsWay Ltd.'s (BWAY) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.